Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricNVSNovartis AGAZNAstraZeneca PLCMRKMerck & Co.
Snapshot
Price$157.83$163.97$150.48
Market cap$261.56B$284.73B$319.99B
Valuation
P/E21.9x25.3x41.2x
Forward P/E20.1x18.9x58.8x
Growth
Revenue growth5.8%9.9%2.9%
EPS growth9.3%33.7%-48.3%
Profitability
Net margin24.1%17.2%13.6%
ROE31.7%22.3%17.9%
Balance sheet & cash
Debt / equity0.77x0.61x0.94x
Free cash flow yield4.2%3.1%2.9%
Dividend yield2.9%1.7%3.0%
Verdict
Investment ratingFavorable· 67Favorable· 62Weak· 35

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearNVStoday $158AZNtoday $164MRKtoday $150
2027$129.35 – $189.71+20% CAGR$164.43 – $241.17+47% CAGR$115.12 – $168.84+12% CAGR
2028$141.34 – $207.29+15% CAGR$219.86 – $322.47+40% CAGR$117.42 – $172.22+7% CAGR
2029$154.44 – $226.51+13% CAGR$293.98 – $431.17+38% CAGR$119.77 – $175.66+5% CAGR
2030$168.75 – $247.51+12% CAGR$393.08 – $576.52+37% CAGR$122.16 – $179.17+4% CAGR
2031$184.40 – $270.45+11% CAGR$525.59 – $770.86+36% CAGR$124.61 – $182.76+4% CAGR
5-yr CAGR3.2% – 11.4%26.2% – 36.3%-3.7% – 4.0%